Shots:

• Exscientia to receive ~$50M as up front- ~$125M as milestones and additional clinical- regulatory- and commercial milestones of over $1.2B along with royalties on net sales of any marketed therapies resulting from the collaboration
• The expanded collaboration has the potential to add to the BMS drug pipeline whilst enhancing Exscientia’s portfolio of shared assets. The alliance will deploy AI to accelerate the discovery of small molecules in multiple therapeutic areas- including oncology & immunology
• Exscientia will take responsibility for AI-design and experimental work necessary to discover drug candidates associated with the collaboration

  Ref: BUSINESS WIRE | Image: BMS